Lessons learnt from many years of experience using anti-D in humans for prevention of RhD immunization and haemolytic disease of the fetus and newborn.
Clin Exp Immunol
; 154(1): 1-5, 2008 Oct.
Article
en En
| MEDLINE
| ID: mdl-18727626
ABSTRACT
For 40 years prophylactic anti-D has been given to D-negative women after parturition to prevent haemolytic disease of the fetus and newborn. Monoclonal or recombinant anti-D may provide alternatives to the current plasma-derived polyclonal IgG anti-D, although none of them have yet proved as effective in phase 1 clinical trials. The variation in efficacy of the antibodies may have been influenced by heterogeneity in glycosylation of anti-D produced from different cell lines. Some aspects of the conduct of the human studies, most notably the use of low doses of anti-D and target D positive red cells in vivo, may aid the design of the clinical development of other immunomodulatory drugs in order to minimize adverse effects.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Sistema del Grupo Sanguíneo Rh-Hr
/
Isoinmunización Rh
/
Recién Nacido
/
Embarazo
/
Eritroblastosis Fetal
/
Isoanticuerpos
Límite:
Female
/
Humans
Idioma:
En
Revista:
Clin Exp Immunol
Año:
2008
Tipo del documento:
Article
País de afiliación:
Reino Unido